Post

Pulse Oximeters - Premarket Notification Submissions 510k

This guidance applies to Class II pulse oximeter devices intended for non-invasive measurement of arterial blood oxygen saturation (SpO2) and pulse rate through various application sites (finger, ear, foot, hand, forehead, back, nose). It covers both continuous monitoring and spot-checking devices, either as stand-alone units or multi-parameter modules. The devices are limited to prescription use.

  1. Determine device classification and applicable product codes
  2. Plan and execute clinical validation studies:
    • SpO2 accuracy testing with required subject diversity
    • Additional studies for special claims (motion, low perfusion)
    • Neonatal validation if applicable
  3. Complete comprehensive performance testing:
    • Pulse rate accuracy
    • Display and alarm functions
    • Environmental conditions
    • EMC testing
  4. Prepare biocompatibility assessment and testing
  5. Develop and validate software according to moderate level of concern requirements
  6. Create complete labeling package with:
    • Clear intended use
    • Detailed instructions
    • Performance specifications
    • Required warnings/cautions
  7. Prepare cleaning/disinfection validation if reusable
  8. Document sterilization processes if provided sterile
  9. Include additional documentation for reprocessed sensors if applicable
  10. Compile 510(k) submission with all required testing and documentation

Key Considerations

Clinical testing

  • In vivo testing required for SpO2 accuracy under laboratory conditions with 10+ healthy subjects
  • 200+ data points distributed across 70-100% SpO2 range
  • Include subjects with range of skin pigmentations (at least 2 darkly pigmented or 15% of pool)
  • Additional convenience sample testing required for neonatal use
  • Clinical testing needed for motion claims validation

Non-clinical testing

  • Bench testing required for pulse rate accuracy
  • Testing needed for low perfusion claims
  • Functional tester validation for OEM technology integration
  • Performance testing for all data outputs, measurements and indicators

Software

  • Moderate level of concern software documentation required
  • Software validation per FDA guidance
  • Additional documentation needed for off-the-shelf software

Labeling

  • Clear intended use statement including patient populations and environments
  • Instructions for use with safety information and device operation details
  • Device specifications including accuracy data and plots
  • Package labeling requirements for sterile/non-sterile status
  • Reprocessing instructions if applicable

Biocompatibility

  • Testing required for skin-contacting materials:
    • Irritation/intracutaneous reactivity
    • Sensitization
    • Cytotoxicity

Safety

  • Electrical safety testing for Type BF/CF applied parts
  • EMC testing required
  • Environmental safety testing needed

Other considerations

  • ISO 80601-2-61:2011: Medical Electrical Equipment - Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment
  • ANSI/AAMI/ISO 11607-1-2:2006: Packaging for terminally sterilized medical devices – Parts 1 and 2
  • IEC 60601-1:2005: Medical electrical equipment - Part 1: General requirements for basic safety and essential performance

Original guidance

  • Pulse Oximeters - Premarket Notification Submissions 510k
  • HTML / PDF
  • Issue date: 2013-03-03
  • Last changed date: 2024-04-11
  • Status: FINAL
  • Official FDA topics: Medical Devices, Premarket, Pediatric Product Development
  • ReguVirta summary file ID: 8758ae8301ea1c620de1243d0f88b60e
This post is licensed under CC BY 4.0 by the author.